#DLL3
LightNews LightNews
marketwirenews.com
Breaking News: ( NASDAQ: #MOLN ) Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action

November 12, 2025 at 8:01 AM
stocktitan.net
#MOLN Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action

https://www.stocktitan.net/news/MOLN/molecular-partners-presents-new-data-for-dll3-targeting-radiotherapy-tk8qs4pe13s7.html
Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action
Molecular Partners (NASDAQ: MOLN) presented new human imaging and mechanism data for MP0712, a DLL3-targeting Radio-DARPin, at TRP Summit Europe on Nov 12, 2025. A named‑patient case from South Africa showed specific tumor uptake at 24 hours and sustained signal over 4 days using 203Pb imaging, with limited kidney and liver exposure. The company filed a Phase 1 IND for MP0712 and expects to initiate the US trial by end‑2025, with initial clinical data anticipated in 2026. Presentation and webcast details were provided for Nov 12, 2025.
www.stocktitan.net
November 12, 2025 at 6:00 AM
linglingtian.bsky.social
🧠 SCLC remains one of the most aggressive cancers.
This new review explores:
🔹 ICIs
🔹 Novel agents like lurbinectedin
🔹 Anti-DLL3 therapies
🔹 Molecular profiling for personalized care
buff.ly/Mmx2f1V
Hope is on the horizon for ES-SCLC.
#LungCancer #SCLC #Oncology #CancerResearch #Immunotherapy
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
buff.ly
November 5, 2025 at 8:15 AM
alcmi.bsky.social
Wow! Zocilurtatug pelitecan (ZL-1310), a next-generation DLL3-targeting antibody-drug conjugate, has demonstrated a 66% objective response rate in patients with extensive-stage small cell lung cancer and asymptomatic brain metastases. #lungcancer
www.aacr.org/about-the-aa...
Investigational Antibody-drug Conjugate Shows Clinical Benefit Against Previously Treated Small Cell Lung Cancer
BOSTON – Zocilurtatug pelitecan (zoci), also known as ZL-1310, an investigational antibody-drug conjugate (ADC) that targets the protein DLL3, demonstrated both safety and capacity to induce…
www.aacr.org
October 31, 2025 at 2:02 PM
stocktitan.net
#MOLN Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025

https://www.stocktitan.net/news/MOLN/molecular-partners-reports-q3-2025-financial-results-and-clinical-urhhb6qnuqfz.html
Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025
IND application filed for MP0712, the Company’s lead Radio-DARPin candidate targeting DLL3 and co-developed with Orano Med, with Phase 1 initiation expected before year end 2025 First patient images from MP0712 compassionate care program to be presented at TRP in November; additional programs
www.stocktitan.net
October 30, 2025 at 8:00 PM
theaacr.bsky.social
An investigational DLL3-targeting antibody-drug conjugate, ZL-1310, showed safety and anticancer responses in patients with extensive-stage small cell lung cancer. Grace K. Dy, MD, of @roswellpark.bsky.social presented phase I clinical trial results at #Targets25. buff.ly/iZCWaXU
October 25, 2025 at 1:33 AM
biotechnetworks.bsky.social
bionetworks Trending: Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study https://zpr.io/9tPLKpLKRxMf
October 24, 2025 at 6:48 PM
elde86.etheirys.social
not Samuel Ramey, but lol
www.youtube.com/watch?v=dlL3...
Nathan Gunn's Top Five Bare-Chested Roles
YouTube video by WQXR
www.youtube.com
October 16, 2025 at 6:47 PM
europesays.bsky.social
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

https://www.europesays.com/2491641/

– Oral presentation to feature new data highlighting the …
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference - EUROPE SAYS
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that a late-breaking abstract (LBA) featuring new
www.europesays.com
October 14, 2025 at 6:15 AM
onclive.bsky.social
Tarlatamab Demonstrates Early Safety and Activity in DLL3+ Neuroendocrine Prostate Cancer @ucsfcancer.bsky.social #pcsm www.onclive.com/view/tarlata...
Tarlatamab Demonstrates Early Safety and Activity in DLL3+ Neuroendocrine Prostate Cancer | OncLive
DeLLpro-300 data provide preliminary evidence for the safety and activity of tarlatamab in DLL3-positive neuroendocrine prostate cancer.
www.onclive.com
October 13, 2025 at 8:51 PM
rickety-shaman.bsky.social
youtube.com/watch?v=DlL3...
Pete Buttigieg Interview
YouTube video by Channel 5 with Andrew Callaghan
youtube.com
October 12, 2025 at 5:30 PM
oncodaily.bsky.social
DLL3 Expression in EGFR NSCLC after SCLC Transformation - Stephen V Liu

@stephenvliu.bsky.social

oncodaily.com/voices/steph...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #DLL3 #NSCLC #SCLC #LungCancer
Stephen V Liu: DLL3 Expression in EGFR NSCLC after SCLC Transformation - OncoDaily
Stephen V Liu: DLL3 Expression in EGFR NSCLC after SCLC Transformation / cancer, Carlos J. Suarez, Farshad Moradi, Gerald J. Berry, Heather A. Wakelee,
oncodaily.com
October 4, 2025 at 8:07 PM
lynn-colorado.bsky.social
youtube.com/watch?v=DlL3...
Pete Buttigieg Interview
YouTube video by Channel 5 with Andrew Callaghan
youtube.com
October 3, 2025 at 3:26 PM
lizziepiflitch.bsky.social
www.youtube.com/watch?v=DlL3...
Pete Buttigieg Interview
YouTube video by Channel 5 with Andrew Callaghan
www.youtube.com
October 3, 2025 at 3:26 AM
brazz99.bsky.social
I do really like Pete.

www.youtube.com/watch?v=DlL3...
Pete Buttigieg Interview
YouTube video by Channel 5 with Andrew Callaghan
www.youtube.com
October 2, 2025 at 3:14 AM
mintbutton26.bsky.social
youtube.com/watch?v=DlL3...
Nice PETE BUTTIGIEG
interview. Nice listen.
#petebuttigieg #ericswalwell #politics #news #peoole#dc #newyork #lgbtq
Pete Buttigieg Interview
YouTube video by Channel 5 with Andrew Callaghan
youtube.com
October 2, 2025 at 1:58 AM
gov.glados.computer
From Crip Mac to Pete Buttigieg... what a journey

www.youtube.com/watch?v=DlL3...
Pete Buttigieg Interview
YouTube video by Channel 5 with Andrew Callaghan
www.youtube.com
October 2, 2025 at 12:59 AM
vlasvilneous.bsky.social
Great interview with Pete Buttigieg by Channel 5.

www.youtube.com/watch?v=DlL3...
Pete Buttigieg Interview
YouTube video by Channel 5 with Andrew Callaghan
www.youtube.com
October 1, 2025 at 10:15 PM
lorimoon.bsky.social
New Pete Buttigieg interview dropped.
www.youtube.com/watch?v=DlL3...
Pete Buttigieg Interview
YouTube video by Channel 5 with Andrew Callaghan
www.youtube.com
October 1, 2025 at 9:42 PM
neilio6.bsky.social
Pete Buttigieg Interview.
www.youtube.com/watch?v=DlL3...
Pete Buttigieg Interview
YouTube video by Channel 5 with Andrew Callaghan
www.youtube.com
October 1, 2025 at 7:07 PM
kittykatprincess.bsky.social
💙💙💙
youtube.com/watch?v=DlL3...
Pete Buttigieg Interview
YouTube video by Channel 5 with Andrew Callaghan
youtube.com
October 1, 2025 at 5:32 PM
roanokeaction.bsky.social
Great Channel 5 with Andrew Callaghan interview with @petebuttigieg.bsky.social.

#TrumpShutdown
#Resist
#FightFascism
#TrumpCrimeFamily
#ReleasetheEpsteinFiles
#EndGazaGenocide
#NoKings
#BeBrave
#FreeUkraine
#FreePortland
#FreeDC
#FreeLA

www.youtube.com/watch?v=DlL3...
Pete Buttigieg Interview
YouTube video by Channel 5 with Andrew Callaghan
www.youtube.com
October 1, 2025 at 5:08 PM
genesndiseases.bsky.social
This study provides insights into NECC treatment through a novel in-vitro #3DOrganoids-TILs co-culture system targeting #DLL3, highlighting its potential as a therapeutic avenue with clinical implications. @fudanuni_official #medsky
#OpenAccess:
www.sciencedirect.com/science/arti...
September 15, 2025 at 5:30 PM
alcmi.bsky.social
A first-in-human trial of the DLL3-directed antibody-drug conjugate SHR-4849 (IDE849) has demonstrated a 59.5% objective response rate and a 90.5% disease control rate in relapsed small cell lung cancer. #lungcancer
medicalxpress.com/news/2025-09...
First-in-human trial shows promising results for antibody-drug conjugate in relapsed small cell lung cancer
A first-in-human Phase I study of SHR-4849 (IDE849), a Delta-like ligand 3 (DLL3)-directed antibody-drug conjugate (ADC), demonstrated manageable safety and early signs of anti-tumor activity in…
medicalxpress.com
September 13, 2025 at 2:02 PM
drvergaro.bsky.social
WO2025179051 discloses DLL3-targeting immunoconjugates using VHH domains linked to cytotoxic isotopes. These constructs enable rapid clearance, improved tumour selectivity, reduced off-target toxicity, and applicability in both therapy (esp. α-emitters) and imaging of DLL3+ cancers.
[Credit: Abdera]
September 11, 2025 at 12:56 PM